Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials

被引:8
|
作者
Bavishi, Chirag [1 ]
Chugh, Yashasvi [2 ,3 ]
Kimura, Takeshi [4 ]
Natsuaki, Masahiro [5 ]
Kaiser, Christoph [6 ]
Gordon, Paul [1 ]
Aronow, Herbert D. [1 ]
Abbott, Jinnette Dawn [1 ]
机构
[1] Rhode Isl Hosp, Lifespan Cardiovasc Inst, Providence, RI 02903 USA
[2] Mt Sinai St Lukes Hosp, New York, NY USA
[3] Mt Sinai West Hosp, New York, NY USA
[4] Kyoto Univ, Grad Sch Med, Sakyo Ku, Kyoto, Japan
[5] Saga Univ, Saga, Japan
[6] Univ Hosp, Basel, Switzerland
关键词
Biodegradable polymer; Durable polymer; Drug-eluting stent; Diabetes; EVEROLIMUS; SAFETY; THROMBOSIS; OUTCOMES; EFFICACY; LEADERS;
D O I
10.1093/ehjqcco/qcz031
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The biodegradable polymer drug-eluting stents (BP-DES) offer controlled drug elution and complete degradation of the polymer over time, eventually lowering the risk for chronic inflammation and neoatherosclerosis, which can be particularly helpful in patients with diabetes. While BP-DES and durable polymer drug-eluting stents (DP-DES) have demonstrated comparable efficacy in all-comers population, their efficacy and safety in patients with diabetes remains uncertain. Methods and results Electronic databases were systematically searched for randomized controlled trials (RCTs) comparing BP-DES with contemporary DP-DES in patients with diabetes. Study investigators were contacted to obtain additional data. The primary outcome was efficacy in terms of target-vessel revascularization (TVR) and target-lesion revascularization (TLR). We also evaluated the following safety outcomes separately: all-cause mortality, cardiac mortality, myocardial infarction (MI), and definite or probable stent thrombosis. Eleven RCTs including 5190 diabetic patients were included. At the longest available follow-up (mean 2.7 years), there was no significant difference in TLR [relative risk (RR): 1.02, 95% confidence interval (CI): 0.85-1.24; P = 0.80] or TVR (RR: 1.04, 95% CI: 0.81-1.34; P = 0.76). Safety outcomes of all-cause mortality, cardiac mortality, and MI were similar between the two groups. Stent thrombosis rates were also similar between BP-DES and DP-DES groups (1.66% vs. 1.83%; RR: 0.84, 95% CI: 0.54-1.31; P = 0.45). The heterogeneity was low and fixed-effect model yielded similar results. Meta-regression analysis showed no relationship between insulin requiring diabetes and difference in TLR or stent thrombosis between BP-DES and DP-DES. Conclusion Overall, BP-DESs have similar safety and efficacy profiles compared to contemporary DP-DES in patients with diabetes.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 50 条
  • [41] Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Drug-Eluting Stents for Patients With Coronary Artery Disease: An Update Meta-Analysis
    Wang, Yanyu
    Dong, Pingshuan
    Li, Ling
    Li, Xiaoling
    Wang, Hongyun
    Yang, Xuming
    Wang, Shaoxin
    Li, Zhuanzhen
    Shang, Xiyan
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (04) : 379 - 385
  • [42] Drug-eluting stents in diabetic patients: Meta-analysis of randomized trials
    Boyden, Thomas F., Jr.
    Gurm, Hitinder
    Nallamothu, Brahmajee
    CIRCULATION, 2006, 113 (21) : E798 - E798
  • [43] Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis
    Juntao Yin
    Yang Li
    Yangyang Chen
    Chaoyang Wang
    Xiaoyong Song
    Scientific Reports, 13
  • [44] Vascular Response to Drug-eluting Stent with Biodegradable Versus Durable Polymer
    Katayama, Yosuke
    Kubo, Takashi
    Akasaka, Takashi
    Aoki, Hiroshi
    Nishiguchi, Tsuyoshi
    Satogami, Keisuke
    Kameyama, Takeyoshi
    Yamano, Takashi
    Yamaguchi, Tomoyuki
    Matsuo, Yoshiki
    Ino, Yasushi
    Kitabata, Hironori
    Tanaka, Atsushi
    Hozumi, Takeshi
    Kimura, Takeshi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (16) : S47 - S47
  • [45] Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials
    Kwong, Joey S. W.
    Yu, Cheuk-Man
    CLINICAL CARDIOLOGY, 2014, 37 (07) : 440 - 453
  • [46] A meta-analysis of randomized controlled trials to compare long-term clinical outcomes of bioabsorbable polymer and durable polymer drug-eluting stents
    Mridha, Naim
    Subhaharan, Deloshaan
    Niranjan, Selvanayagam
    Rashid, Mohammed K.
    Psaltis, Peter
    Singh, Kuljit
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2019, 5 (02) : 105 - 113
  • [47] A COMPARISON OF THE ULTRATHIN ORSIRO HYBRID SIROLIMUS-ELUTING STENT WITH CONTEMPORARY DRUG-ELUTING STENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Forrestal, Brian J.
    Lipinski, Michael
    Iantorno, Micaela
    Torguson, Rebecca
    Waksman, Ron
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1113 - 1113
  • [48] Safety and Efficacy of Biodegradable Drug-Eluting vs. Bare Metal Stents: A Meta-Analysis from Randomized Trials
    Yin, Yangguang
    Zhang, Yao
    Zhao, Xiaohui
    PLOS ONE, 2014, 9 (06):
  • [49] A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials
    Lipinski, Michael J.
    Forrestal, Brian J.
    Iantorno, Micaela
    Torguson, Rebecca
    Waksman, Ron
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2018, 19 (01) : 5 - 11
  • [50] COMPARISON OF BIODEGRADABLE DRUG ELUTING POLYMER STENTS AND DURABLE POLYMER DRUG ELUTING STENT FOR THE TREATMENT OF CAD: A META-ANALYSIS OF RCT'S
    Garcia, Daniel
    Ansari, Mohammad
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 101 - 101